11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care

Clinical Definitions, Epidemiology & Impact

Postpartum haemorrhage (PPH) remains one of the leading preventable causes of maternal morbidity and mortality worldwide and across the Caribbean region. Clinicians preparing for the CAMC registration examination must master both the clinical definitions and the rapid, systematic resuscitation protocols required when torrential obstetric bleeding occurs.

Clinical Classification

• Primary Postpartum Haemorrhage: Defined as blood loss of >= 500 mL following a vaginal delivery or >= 1000 mL following a caesarean delivery occurring within 24 hours of childbirth. In clinical practice, any volume of blood loss that causes hemodynamic instability (hypotension, tachycardia, pallor, oliguria) must be treated emergently as primary PPH regardless of the measured volume.
  • Minor PPH: Estimated blood loss between 500 mL and 1000 mL without hemodynamic instability.
  • Major PPH: Estimated blood loss > 1000 mL, further stratified into moderate (1000 to 2000 mL) and severe (> 2000 mL or bleeding associated with shock).
• Secondary Postpartum Haemorrhage: Defined as excessive or abnormal uterine bleeding occurring between 24 hours and 6 weeks postpartum. The predominant etiologies include retained products of conception (RPOC, such as cotyledons or membranes), postpartum endometritis, subinvolution of the placental implantation site, and rarely, gestational trophoblastic disease (choriocarcinoma).

Pitfalls in Estimation & Hemodynamic Assessment

Visual estimation notoriously underestimates obstetric blood loss by 30% to 50%, particularly when blood is concealed in pelvic hematomas, soaked into surgical drapes, or mixed with amniotic fluid. Relying solely on blood pressure changes is perilous because physiological hypervolemia of pregnancy allows healthy young parturients to compensate for massive intravascular loss without hypotension until 30% to 40% of circulating blood volume is lost.

The Shock Index (SI), calculated as Heart Rate divided by Systolic Blood Pressure (HR / SBP), serves as an early, sensitive bedside indicator of occult hypoperfusion:

• Normal non-pregnant SI: 0.5 to 0.7
• Normal pregnant SI at term: <= 0.9
• SI >= 0.9 indicates significant hypovolemia and impending decompensation.
• SI >= 1.0 indicates massive blood loss, high transfusion requirement, and urgent need to activate the massive obstetric hemorrhage protocol.

Active Management of the Third Stage of Labour (AMTSL)

The third stage of labour spans the interval between the complete delivery of the neonate and the complete expulsion of the placenta and fetal membranes. Routine implementation of Active Management of the Third Stage of Labour (AMTSL) reduces the incidence of primary PPH by up to 60% across both low- and high-resource healthcare environments.

The Three Core Components of AMTSL

1. Prophylactic Uterotonic Administration: Administer 10 International Units (IU) of Oxytocin by intramuscular (IM) injection or slow intravenous (IV) bolus immediately following the delivery of the anterior shoulder or within 1 minute of neonatal delivery. Oxytocin is the global agent of choice because it stimulates rhythmic upper-segment uterine contractions within 2 to 3 minutes without causing sustained hypertension.
2. Controlled Cord Traction (CCT): Performed using the Brandt-Andrews maneuver. Following cord clamping near the perineum, the clinician places one hand immediately above the symphysis pubis, applying firm, continuous upward and backward counter-traction on the lower uterine segment while the other hand exerts gentle, sustained downward traction on the umbilical cord during a uterine contraction. Controlled traction must never be applied without suprapubic counter-traction, as traction on an uncontracted, relaxed uterus risks catastrophic acute uterine inversion.
3. Fundal Uterine Massage & Tone Assessment: Immediately following complete placental expulsion, the uterine fundus is palpated through the abdominal wall and massaged until it is firmly contracted. Uterine tone and lochial flow must be reassessed every 15 minutes for the first 2 hours postpartum.

Systematic Placental Inspection

Immediately following expulsion, the placenta must be examined in a well-lit delivery room:

• Maternal Surface: Reapproximate all fleshy placental cotyledons. Any missing cotyledon or irregular raw defect strongly indicates retained placental tissue.
• Fetal Surface: Inspect the chorionic and amniotic membranes for completeness. Inspect vessels radiating from the umbilical cord insertion; vessels coursing across the membranes to the placental margin suggest the presence of a succenturiate lobe that may have detached and remained inside the uterine cavity.

Etiological Framework: The "4 Ts"

When primary PPH occurs, immediate diagnostic appraisal centers on the classic "4 Ts" mnemonic to identify the underlying driver:

Stepwise Resuscitation & Medical Management of Uterine Atony

When PPH is diagnosed, start uterine massage, uterotonic therapy, IV tranexamic acid, fluids and genital-tract examination promptly in parallel, while mobilizing senior help and escalating care. TXA must not await failure of sequential uterotonics. Delay in mobilizing experienced personnel is the single greatest determinant of preventable maternal death.

+-----------------------------------------------------------------------------------------+
|                         STEP 1: ACTIVATE PROTOCOL & RESUSCITATE                         |
|  - Call senior obstetrician, anesthetist, labor ward team ("Code Crimson")             |
|  - Administer high-flow O2 (10-15 L/min via non-rebreather)                             |
|  - Insert TWO 14G or 16G IV cannulae; draw FBC, Clotting, Fibrinogen, Crossmatch 4-6 U  |
|  - Rapid warm crystalloids (Ringer's/Hartmann's); insert indwelling Foley catheter      |
+-----------------------------------------------------------------------------------------+
                                             |
                                             v
+-----------------------------------------------------------------------------------------+
|                    STEP 2: BIMANUAL COMPRESSION, UTEROTONIC & EARLY TXA                 |
|  - Immediate internal/external bimanual uterine compression                             |
|  - Oxytocin: 10 IU slow IV + infusion 20-40 IU in 1000 mL crystalloid                 |
|  - TXA: 1 g IV over 10 minutes promptly; start within 3 hours of BIRTH                 |
+-----------------------------------------------------------------------------------------+
                                             |
                                             v
+-----------------------------------------------------------------------------------------+
|                    STEP 3: ADDITIONAL UTEROTONICS IF ATONY PERSISTS                |
|  - If normotensive: Ergometrine 0.5 mg IM or slow IV (CONTRAINDICATED in HTN/Preeclampsia)|
|  - If non-asthmatic: Carboprost 0.25 mg deep IM (CONTRAINDICATED in active Asthma)      |
|  - Misoprostol: 800-1000 mcg rectally or 600-800 mcg sublingually                       |
+-----------------------------------------------------------------------------------------+
                                             |
                                             v
+-----------------------------------------------------------------------------------------+
|                    STEP 4: MECHANICAL TAMPONADE & SURGICAL EXPLORATION                  |
|  - Intrauterine balloon tamponade (Bakri balloon 300-500 mL saline or condom catheter)  |
|  - Transfer to theater: EUA, B-Lynch compression sutures, vessel ligation, hysterectomy |
+-----------------------------------------------------------------------------------------+

Resuscitation Fundamentals

1. Mobilize the Multidisciplinary Team: Call for senior obstetric, anesthetic, and nursing support, alongside the regional hospital blood bank.
2. Airway, Breathing, Circulation (ABC): Position the patient flat (or with 15-degree left lateral tilt if undelivered). Administer 100% high-flow oxygen via a non-rebreather reservoir mask.
3. Vascular Access & Laboratory Workup: Place two large-bore IV cannulae (14-gauge orange or 16-gauge grey) into prominent antecubital veins. Immediately draw blood for:
   • Complete Blood Count (hemoglobin, hematocrit, platelet count)
   • Coagulation screen (Prothrombin Time [PT], Activated Partial Thromboplastin Time [aPTT], International Normalized Ratio [INR], and quantitative plasma fibrinogen)
   • Serum electrolytes, urea, creatinine, and blood lactate
   • Blood group and emergency crossmatch for 4 to 6 units of Packed Red Blood Cells (PRBCs)
4. Volume Resuscitation: Infuse warmed isotonic crystalloid (Hartmann's solution or normal saline) via pressure bags. Limit crystalloid infusion to 2000 to 3000 mL prior to blood product availability to prevent hypothermia, hemodilution, and worsening of the lethal triad (hypothermia, acidosis, coagulopathy). Activate Massive Transfusion Protocols (MTP) targeting a 1:1:1 balanced ratio of PRBCs, Fresh Frozen Plasma (FFP), and Platelets if severe bleeding persists.
5. Bladder Decompression: Insert an indwelling Foley catheter connected to an hourly urometer. A full bladder displaces the uterus laterally and superiorly, physically impeding myometrial contraction. Hourly urine output serves as an essential index of renal perfusion (target >= 0.5 mL/kg/h).
6. Bimanual Uterine Compression: Insert a gloved hand into the vagina, form a closed fist in the anterior fornix, and compress the anterior wall of the uterus upward while the other hand exerts firm abdominal pressure on the posterior aspect of the fundus, squeezing the myometrial vascular bed between the hands.

Uterotonics for Atony & Early Antifibrinolytic Treatment

1. Oxytocin:
   • Regimen: 10 IU slow IV injection (over 1 to 2 minutes), followed immediately by an intravenous infusion of 20 to 40 IU of oxytocin in 1000 mL of crystalloid running at 125 to 250 mL/h.
   • Mechanism: Binds to myometrial G-protein coupled oxytocin receptors, mobilizing intracellular calcium to produce rhythmic uterine contractions.
   • Caution: Rapid undiluted IV bolus injection must be strictly avoided; it induces sudden profound systemic vasodilation, acute hypotension, and reflex tachycardia.
2. Ergot Uterotonics: Ergometrine or Methylergonovine:
   • Regimens differ: Ergometrine 0.5 mg IM, or slow IV when appropriate under protocol; methylergonovine 0.2 mg IM, repeated every 2–4 hours if required. Do not substitute their doses.
   • Mechanism: Ergot alkaloid acting as an agonist at alpha-adrenergic, serotonergic (5-HT2), and dopaminergic receptors, inducing sustained, tetanic, basal uterine smooth muscle contractions.
   • ABSOLUTE CONTRAINDICATION: Hypertension, gestational hypertension, pre-eclampsia, eclampsia, and coronary artery disease. Ergometrine produces intense arterial vasoconstriction and can trigger fatal hypertensive encephalopathy, intracranial haemorrhage, acute pulmonary edema, or coronary vasospasm.
3. Carboprost Tromethamine (15-methyl Prostaglandin F2-alpha / Hemabate):
   • Regimen: 0.25 mg (250 micrograms) administered by deep intramuscular injection or direct intramyometrial injection (avoid IV administration). Can be repeated every 15 to 90 minutes up to a cumulative maximum dose of 2.0 mg (8 doses).
   • Mechanism: Synthetic prostaglandin F2-alpha analog producing intense myometrial contraction and vascular constriction.
   • ABSOLUTE CONTRAINDICATION: Active bronchial asthma or history of severe bronchospasm. Carboprost induces potent bronchial smooth muscle constriction, provoking life-threatening status asthmaticus and profound ventilation-perfusion mismatch.
   • Adverse Effects: Profuse watery diarrhea, nausea, vomiting, transient pyrexia, flushing, and systemic hypertension.
4. Misoprostol (Prostaglandin E1 Analog):
   • Regimen: 800 to 1000 micrograms administered rectally, or 600 to 800 micrograms sublingually/orally.
   • Mechanism: Synthetic PGE1 analog that binds myometrial EP receptors to produce prolonged uterine contractions within 20 to 30 minutes.
   • Clinical Value: Highly resilient, room-temperature stable formulation requiring no cold-chain storage. Invaluable in rural primary clinics across Caribbean islands lacking refrigeration facilities.
   • Adverse Effects: High-grade shivering (rigors) and transient hyperpyrexia (up to 40°C).
5. Tranexamic Acid (TXA):
   • Regimen: 1 gram (1000 mg) IV in 100 mL of normal saline infused over 10 minutes. A second dose of 1 g IV is administered if bleeding continues after 30 minutes or recurs within 24 hours.
   • Evidence & Timing: The landmark international WOMAN Trial (World Maternal Antifibrinolytic Trial) demonstrated that early administration of tranexamic acid within 3 hours of delivery reduces maternal death from bleeding by approximately 30% without increasing venous or arterial thromboembolic events. Administration initiated beyond 3 hours offers no clinical survival benefit and may increase adverse outcomes.

Mechanical Tamponade & Surgical Interventions

When pharmacotherapy fails to achieve hemostasis, the clinician must proceed immediately to mechanical and surgical interventions before uncorrectable coagulopathy supervenes.

Intrauterine Balloon Tamponade (Bakri Balloon)

• Procedure: A sterile silicone Bakri balloon is inserted through the cervix into the uterine cavity under transabdominal ultrasound guidance. The balloon is inflated with 300 to 500 mL of sterile warmed saline (never air or CO2).
• The Tamponade Test: Once inflated, if bleeding from the cervical canal and the balloon drainage port ceases within 15 minutes, the tamponade test is positive. The balloon exerts hydrostatic pressure exceeding systemic capillary pressure, compressing the open myometrial venous sinuses.
• Lower-Cost Devices: A sterile condom-catheter balloon may be used under an established protocol; equivalence to commercial devices is not established. Balloon tamponade requires trained staff, monitoring, first-response treatment, reasonable exclusion of retained tissue/trauma, and immediate access to blood and surgical rescue. Persistent bleeding or deterioration requires escalation without delay.
• Management: The balloon is maintained for 12 to 24 hours under continuous prophylactic broad-spectrum antibiotic coverage and low-dose oxytocin infusion, followed by gradual deflation and removal in theater.

Surgical Salvage in Theater

If mechanical tamponade fails or is unavailable, the patient must be transferred immediately to the operating theater for laparotomy:

1. Uterine Compression Sutures (B-Lynch Suture): Involves applying vertical brace-like compression sutures traversing through the anterior and posterior uterine walls, acting like a pair of suspenders to compress the myometrium.
2. Systematic Pelvic Devascularization: Stepwise bilateral ligation of the ascending branches of the uterine arteries (O'Leary sutures), followed if necessary by ligation of the utero-ovarian anastomoses.
3. Internal Iliac (Hypogastric) Artery Ligation: Ligation of the anterior division of the internal iliac artery reduces pelvic arterial pulse pressure by approximately 85%, converting high-pressure pulsatile flow into low-pressure venous-like seepage.
4. Emergency Peripartum Hysterectomy: Subtotal (supracervical) or total abdominal hysterectomy is the definitive, life-saving salvage procedure. The decision must be made decisively by the most senior obstetrician before the development of hypothermia, refractory acidosis (pH < 7.1), and profound DIC.

Normal Puerperium Physiology & Postpartum Care

The puerperium spans the 6-week (42-day) period immediately following the delivery of the placenta, during which maternal anatomical, physiological, and biochemical adaptations to pregnancy resolve and the reproductive organs return to their non-pregnant baseline state. Mastery of normal puerperal physiological mechanisms enables the obstetrician to distinguish expected adaptations from life-threatening puerperal pathologies.

Uterine Involution: Mechanics, Timeline & Clinical Monitoring

Uterine involution is the rapid physiological process by which the gravid uterus regresses in size, volume, and weight back to its pre-pregnancy state. This involution is mediated by two primary mechanisms:

1. Intense Myometrial Contraction and Retraction: Sustained tonic contractions constrict intramyometrial spiral arterioles and venous sinuses ('living ligatures'), producing local ischemia and hemostasis.
2. Myometrial Autolysis: Proteolytic lysosomal enzymes degrade the massive intracellular cytoplasm of hypertrophied myometrial myocytes. The number of myometrial cells remains largely constant, but their size shrinks dramatically. The protein degradation products are absorbed into systemic circulation and excreted via maternal kidneys.

Chronological Timeline of Uterine Involution:

• Immediately Postpartum: Following placental expulsion, the uterine fundus is firm, well-contracted, and palpable at or just below the maternal umbilicus (approximately equivalent to a 20-week gravid uterus). The uterine weight is approximately 1,000 g.
• End of Week 1: The fundus descends midway between the umbilicus and the superior border of the symphysis pubis; weight decreases to 500 g.
• Days 10 to 14: The fundal height descends by approximately 1 cm (or one fingerbreadth) every 24 hours. By post-delivery days 10 to 14, the fundus has completely descended beneath the pelvic brim into the true pelvis and is no longer palpable abdominally above the pubic symphysis.
• 6 Weeks Postpartum: The uterus has completely returned to its non-pregnant adult size, weighing approximately 50 to 60 g.

Endometrial Regeneration: Placental separation occurs through the spongy layer of the decidua basalis. The superficial decidual layer becomes necrotic and sloughs off within the lochial discharge. The deep basal layer containing fundic glands remains intact and undergoes rapid cellular proliferation. Complete re-epithelialization of the non-placental endometrium is accomplished by day 10 to 14 postpartum. In contrast, the placental implantation site (approximately 8 to 9 cm wide at delivery) requires up to 6 weeks for complete healing via exfoliation and an upward undermining growth of surrounding endometrial margins, which prevents fibrotic scar formation that would compromise subsequent implantations. Delayed involution (subinvolution) typically results from retained placental fragments or persistent low-grade puerperal endometritis.

Lochia Progression: Characteristics, Stages & Pathological Deviations

Lochia represents the physiological puerperal vaginal discharge comprising decidual debris, maternal blood, mucosal transudate, and cervical secretions. Normal lochia progresses through three distinct sequential chronological phases:

Pathological Lochial Deviations & Red Flags:

• Foul, Offensive Odor: Normal lochia carries a characteristic fleshy odor resembling normal menstrual flow. A foul, putrid, or offensive odor is the hallmark of acute puerperal endometritis, typically driven by polymicrobial ascending vaginal flora (Group B Streptococcus, Bacteroides, Peptostreptococcus, Escherichia coli). It mandates urgent bimanual examination, high vaginal and endocervical swabs, and broad-spectrum parenteral antibiotics (e.g., Clindamycin 900 mg IV q8h + Gentamicin 5 mg/kg IV daily).
• Persistent Lochia Rubra Beyond Day 14: Strongly suggests subinvolution of the placental bed or retained products of conception (RPOC), predisposing to secondary postpartum hemorrhage. Pelvic ultrasound is indicated to exclude retained tissue and assess endometrial vascularity.
• Sudden Profuse Bleeding Following Lochia Alba: Suggests secondary PPH, placental eschar detachment, or rarely, choriocarcinoma.

Lactation Physiology: Neuroendocrine Reflex Arcs

Human lactation requires two synchronized, reciprocal neuroendocrine reflex arcs involving the anterior and posterior pituitary glands:

+-----------------------------------------------------------------------------------------+
|                        NEUROENDOCRINE CONTROL OF LACTATION                              |
+-----------------------------------------------------------------------------------------+
                                             |
                  +--------------------------+--------------------------+
                  |                                                     |
                  v                                                     v
      [ MILK PRODUCTION / SYNTHESIS ]                               [ MILK EJECTION / LET-DOWN ]
       Anterior Pituitary: PROLACTIN                                 Posterior Pituitary: OXYTOCIN
                  |                                                     |
  - Synthesized by acidophilic lactotrophs             - Synthesized in paraventricular & supraoptic
  - Gestation: High progesterone inhibits                hypothalamic nuclei; stored in neurohypophysis
    copious prolactin-mediated milk secretion                       - Stimulus: Nipple mechanoreceptors / infant suckling
  - Expulsion of placenta: Progesterone drops            (also conditioned auditory/visual cues)
    precipitously -> Allows secretory activation             - Rapid neural afferents (T4-T6) to hypothalamus
  - Suckling: Intercostal nerves (T4-T6) ->            - Pulsatile oxytocin release into bloodstream
    Hypothalamus -> Suppresses dopamine (PIF)          - Targets G-protein receptors on MYOEPITHELIAL CELLS
  - Prolactin spikes -> Stimulates alveolar              surrounding mammary alveoli & lactiferous ducts
    epithelial cells to synthesize milk proteins       - Myoepithelial contraction -> Forces alveolar milk
    (casein, lactalbumin), lactose, and lipids           into lactiferous sinuses & nipple orifices
  - Acts on NEXT feed (replenishes reservoir)          - Simultaneously stimulates myometrial 'after-pains'

1. Prolactin & Milk Synthesis (Galactopoiesis):
   • Gestational Inhibition: Throughout pregnancy, maternal serum prolactin progressively rises up to ten-fold under the influence of placental estrogens. However, high progesterone and estrogen levels inhibit copious milk secretion despite elevated prolactin. They oppose prolactin-mediated secretory activation; they do not competitively occupy prolactin receptors.
   • Lactogenesis Stage II (Secretory Activation): Following delivery of the placenta, circulating progesterone and estrogen levels plunge precipitously within 24 to 48 hours. This hormonal withdrawal permits prolactin-mediated secretory activation and copious milk production (typically manifesting as breast fullness and engorgement between 48 and 72 hours postpartum).
   • The Suckling Arc for Prolactin: Nipple stimulation by the nursing infant activates cutaneous mechanoreceptors, sending afferent somatosensory nerve signals via the thoracic spinal cord (T4-T6) to the arcuate and periventricular nuclei of the hypothalamus. This signal inhibits the secretion of dopamine (which serves as physiological Prolactin-Inhibiting Factor, PIF). Suppression of dopamine in hypophyseal-portal blood disinhibits anterior pituitary lactotrophs, triggering episodic spikes in prolactin release that stimulate alveolar epithelial cells to produce milk for the subsequent feeding.
2. Oxytocin & Milk Ejection ("Let-Down Reflex"):
   • Hypothalamic Synthesis & Storage: Oxytocin is synthesized by magnocellular neurosecretory cells within the supraoptic and paraventricular nuclei of the hypothalamus and transported along the hypothalamo-hypophyseal tract to be stored in the posterior pituitary gland (neurohypophysis).
   • The Let-Down Arc: Infant suckling generates immediate afferent neural impulses ascending the anterolateral spinothalamic tracts, triggering instantaneous, pulsatile oxytocin secretion into systemic capillaries within seconds. Conditioned psychological reflexes (e.g., hearing the infant cry, holding the infant, or the mother preparing to nurse) can also trigger oxytocin release via limbic cortical pathways; conversely, extreme maternal pain, emotional stress, anxiety, or hypothermia stimulates sympathetic catecholamine release that inhibits this let-down reflex.
   • Action on Myoepithelial Cells: Circulating oxytocin binds specifically to G-protein coupled oxytocin receptors on the stellate myoepithelial cells that envelop the mammary alveoli and small interlobular ducts. Contraction of these myoepithelial cells dramatically elevates intra-alveolar pressure, actively squeezing milk into the larger lactiferous sinuses and propelling it through the nipple pores.
   • Postpartum Uterine Contractions ("After-Pains"): Circulating oxytocin simultaneously stimulates uterine myometrial receptors, inducing distinct postpartum cramping during nursing sessions. This beneficially promotes rapid uterine involution and minimizes late secondary PPH.

Postpartum Contraceptive Selection & Medical Eligibility

Fertility can return rapidly following delivery. Non-lactating mothers may ovulate within 21 to 28 days postpartum, making contraception counseling essential prior to hospital discharge.

1. Progestin-Only Methods:
   • Formulations: Progestin-only pills (POPs, e.g., desogestrel 75 mcg daily), Depot Medroxyprogesterone Acetate (DMPA 150 mg IM every 12 weeks), Subdermal etonogestrel/levonorgestrel implants (Nexplanon, Jadelle), and Levonorgestrel intrauterine systems (LNG-IUS / Mirena).
   • Clinical Eligibility: Progestin-only pills and implants can generally start immediately postpartum, including during breastfeeding. WHO 2025 also permits DMPA in breastfeeding women before 6 weeks as MEC 2: benefits generally outweigh risks. MEC 1, unlike 2, means no restriction. DMPA may increase VTE risk, so consider individual thrombosis risks and alternatives. These methods are generally compatible with breastfeeding; follow the separate postpartum timing rules below for intrauterine methods.
2. Combined Hormonal Contraceptives (CHCs: COCs, Transdermal Patch, Vaginal Ring):
   • Thromboembolic Hazards: Pregnancy and the early puerperium represent an intensely hypercoagulable state characterized by elevated fibrinogen, factors VII, VIII, and X, suppressed protein S activity, and venous stasis. The relative risk of VTE is elevated 20- to 80-fold in the early postpartum period compared to non-pregnant baseline.
   • Contraindication Timeline:
     • Postpartum < 21 Days (3 Weeks): MEC Category 4 (ABSOLUTE CONTRAINDICATION) for all postpartum women, regardless of breastfeeding status, due to the unacceptable risk of fatal pulmonary embolism.
     • Postpartum 21 to 42 Days (3 to 6 Weeks): MEC Category 3 or 4 in women with additional venous thromboembolism risk factors (e.g., age >= 35 years, BMI >= 30 kg/m2, caesarean delivery, severe pre-eclampsia, active smoking, immobility, or major postpartum hemorrhage).
   • Impact on Lactation: Exogenous estrogens suppress anterior pituitary prolactin sensitivity and reduce breast milk volume and duration of lactation. In breastfeeding women, CHCs should generally be avoided until at least 6 months postpartum or until weaning is established.
3. Intrauterine Devices (IUDs):
   • Timing: Both Copper IUDs and LNG-IUS can be safely inserted within 48 hours of delivery (postplacental or pre-discharge), or delayed until 4 to 6 weeks postpartum (interval insertion). Insertion between 48 hours and 4 weeks postpartum is generally avoided due to heightened risks of uterine perforation and expulsion while the myometrium is soft and undergoing active involution.
4. Lactational Amenorrhea Method (LAM):
   • Provides approximately 98% contraceptive protection, but ONLY when all three of the following strict criteria are continuously and simultaneously fulfilled:
     1. Exclusive or Near-Exclusive Breastfeeding: Breastfeed frequently day and night, with intervals no longer than 4 hours by day or 6 hours at night. Nearly exclusive feeding allows limited supplements while the vast majority of feeds (at least 85%) remain breastfeeds.
     2. Complete Amenorrhea: Complete absence of maternal menstrual vaginal bleeding after 56 days (8 weeks) postpartum.
     3. Infant Age < 6 Months: The infant is under 6 months of age.
   • Clinical Rule: If any criterion is no longer met—for example, menses return, feeding intervals lengthen, breastfeeding is no longer nearly exclusive, or the infant reaches 6 months—start another reliable contraceptive method. Limited supplementation alone does not automatically invalidate LAM.

Routine Postpartum Monitoring & Maternal Mental Health Triage

Routine postnatal surveillance must systematically evaluate maternal physiological recovery, perineal healing, and psychological well-being.

• Perineal & Operative Wound Management:
  • The perineum is inspected daily using the REEDA scale (Redness, Edema, Ecchymosis, Discharge, and Approximation of wound edges). Episiotomy and perineal tear repairs (first- to fourth-degree) require strict hygiene, scheduled oral analgesia (paracetamol and NSAIDs, which do not impair lactation), warm sitz baths, and oral stool softeners (docusate sodium) to avoid straining and wound dehiscence.
• Mental Health Triage: Distinguishing Blues, Depression & Psychosis: Maternal mental health disorders represent one of the most underdiagnosed contributors to postpartum morbidity. Clinicians must master the clear differentiation between the three primary conditions: